Impact of Decision-Framing in Psoriasis

NCT04136314 | Completed

• 1 other identifier: HS-19-00740
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Rationale: Shared decision-making models between clinicians and patients are critical to improving healthcare delivery and adherence to medication. One type of model, decision framing, is rarely studied in medicine. Decision framing is the way that a choice is worded. In a clinical context, patient choices can be worded positively, or "gain-framed", to explain the benefits of a therapy or negatively, or "loss-framed", to explain the risks of not taking a therapy. Previous literature suggests that decision-framing can significantly influence patients' decision-making regarding their healthcare. However, a critical gap exists in understanding how decision framing affects psoriasis patients' preferences for therapies. Objective: Determine whether loss-framed messages lead to greater therapy acceptance as compared to gain-framed messages among adults with psoriasis. Study population: 90 adults with psoriasis will be enrolled from USC ambulatory clinics and the general public. Intervention: Subjects will be exposed to gain-framed or loss-framed messages regarding psoriasis therapies. Specifically, gain-framed messages will explain the expected benefits of taking the psoriasis therapy and loss-framed messages will explain the potential risks of not taking the psoriasis therapy. Study Methodology: Cross-sectional single-intervention survey.

Conditions

Psoriasis Vulgaris; Psoriatic Arthritis; Psoriasis

Keywords

Decision-Framing; Prospect Theory; Medication Preferences

Outcome Measures

Primary Outcomes (1)

• Gain-framed vs. Loss-framed Survey Responses

  Difference in survey responses based on exposure to gain-frame or loss-frame question. After exposure to the positively or negatively framed question, subjects will be asked how likely they would agree to receive a hypothetical injectable medication. The subjects will answer with a Likert scale ranging from 0 to 10, with 0 indicating they will definitely not want the medication and 10 indicating they will definitely want the medication. Each enrolled subject will complete the survey only once.

  Up to 14 weeks

Secondary Outcomes (2)

• Effect of Psoriatic Arthritis on Survey Responses

  Up to 14 weeks

• Effect of Sex on Survey Responses

  Up to 14 weeks

Study Arms (2)

Gain-Frame Survey [A]

EXPERIMENTAL

Behavioral: Decision-Framed Survey

Loss-Frame Survey [B]

EXPERIMENTAL

Behavioral: Decision-Framed Survey

Interventions

Decision-Framed Survey BEHAVIORAL

Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to \[A\] a gain-framed message or \[B\] a loss-framed message.

Gain-Frame Survey [A]; Loss-Frame Survey [B]

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Greater than 18 years of age
• Has physician diagnosed psoriasis with or without psoriatic arthritis
• Able to read and write in either English or Spanish

You may not qualify if:

• Less than 18 years of age
• Does not have physician diagnosed psoriasis
• Unable to read and respond to questionnaires in English or Spanish

Sponsors & Collaborators

• University of Southern California: lead

Study Sites (1)

University of Southern California

Los Angeles, California, 90089, United States

Location

MeSH Terms

Conditions

Arthritis, Psoriatic; Psoriasis

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Masking Details: Primary/blinded investigator will be blinded to randomization of subject to either group A (gain-framed) or group B (loss-framed) arms. Blinded party will create the randomization master list and provide a given subject's arm allocation to the primary/unblinded investigator once that subject has been enrolled.
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 16, 2019
• First Posted: October 23, 2019
• Study Start: October 21, 2019
• Primary Completion: November 30, 2019
• Study Completion: January 31, 2020
• Last Updated: December 15, 2022

Record last verified: 2022-12

Locations

US (1)